- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Skye Bioscience, Inc. Common Stock(SKYE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SKYE
11/19/2026: SKYE (1-star) is currently NOT-A-BUY. Pass it for now.
Skye Bioscience is a clinical-stage biotechnology company focused on developing novel therapeutics targeting the endocannabinoid system to treat metabolic disorders and obesity. The company's primary value proposition rests on nimacimab, a first-in-class peripheral CB1 inhibitor showing promising potential for additive weight loss when combined with existing incretin therapies. Key strengths include its differentiated non-incretin mechanism and focused clinical strategy, while major risks involve being pre-revenue, having a concentrated pipeline, and experiencing continuous cash burn requiring equity dilution. The stock suits risk-tolerant growth or momentum investors willing to weather high volatility ahead of upcoming clinical data milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Offers high potential growth tied to clinical trial catalysts, but lacks commercial revenue. |
| Momentum investor | Strong fit while signal remains positive | Short-term momentum can spike dramatically around clinical trial data readouts and equity market sentiment. |
| Value investor | Weak fit | The company has no earnings, book value is small relative to cash burn, and valuation is entirely speculative. |
| Dividend investor | Weak fit | Skye Bioscience is pre-revenue and does not pay dividends. |
| Low-risk investor | Weak fit | High clinical, regulatory, and financial volatility expose low-risk investors to severe capital loss. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock experiences extreme price swings driven by clinical updates, biotech sector sentiment, and capital raises. |
| Valuation risk | High | Valuation is based entirely on speculative future clinical success rather than current revenues or earnings. |
| Competition risk (metabolic drug development) | High | The obesity and metabolic therapeutic space is heavily crowded with well-funded competitors and established therapies. |
| Business quality | Medium / high | As a clinical-stage research entity, it has yet to prove commercial product viability or manufacturing scale. |
| Dividend income | Low / none | No dividend is paid or anticipated in the foreseeable future. |
| Execution risk | High | Success relies entirely on successfully executing complex clinical trials and securing regulatory approvals. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.56M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 94.5K shares | Beta 3.15 | 52 Weeks Range 0.26 - 2.25 | Updated Date 11/19/2026 |
52 Weeks Range 0.26 - 2.25 | Updated Date 11/19/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.56 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 61.0%
- Active BUY / eligible
- 64 / 105
- 30-Day BUY Count Change
- +16
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 44.7%
- Active BUY / eligible
- 17 / 38
- 30-Day BUY Count Change
- +9
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 24.83% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Therapeutics & Licensing | Future potential commercial sales, milestone payments, and licensing revenues derived from drug candidates like nimacimab once approved. | The company currently makes zero revenue and relies on equity financing to fund its drug development. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -258.70K | Price to Sales(TTM) 117.9 |
Enterprise Value -258.70K | Price to Sales(TTM) 117.9 | ||
Enterprise Value to Revenue 220.74 | Enterprise Value to EBITDA -2.56 | Shares Outstanding 4.42M | Shares Floating 3.14M |
Shares Outstanding 4.42M | Shares Floating 3.14M | ||
Percent Insiders 4.99 | Percent Institutions 44.6 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

